BIOELECTRONICS CORP - BIEL STOCK NEWS

BioElectronics announces positive results from a study on its FDA-cleared PSWT device for treating osteoarthritis in dogs. 96% of treated dogs showed improvement in passive range of motion and behavioral changes compared to the placebo group. The study, published in Veterinary Medicine & Science, highlights the potential of BioElectronics' technology in enhancing the quality of life for canines with OA.

BioElectronics Corporation announces positive results in a study on treating phantom and residual limb pain with its pulsed shortwave therapy device.

BioElectronics Corporation provides an update on clinical trial progress and potential legal action against MundiPharma. The company discusses ongoing clinical trials, completed studies under peer review, manufacturing improvements, and sales activities.

BioElectronics Corp. (OTC: BIEL) has seen good progress on the research side, with positive results from various clinical studies and a new product design. However, the sales front has been more mixed, with new distributors in some regions but failed talks with a major distributor in Asia and the CIS countries.

BioElectronics Corporation (BIEL) has received an initial purchase order from Stada MENA, marking a significant step for its product distribution. The company completed promising clinical trials revealing a 45% pain reduction in dogs with osteoarthritis and a 67% pain relief rate in phantom limb pain patients using its RecoveryRx device. Furthermore, their ActiPatch device showed better pain relief for temporomandibular joint disorders compared to traditional treatments. The firm aims to explore these markets further, capitalizing on the growing demand for effective medical technologies.

BioElectronics Corporation (BIEL) announced a distribution agreement with Spain's PRIM Group for its RecoveryRx device. This device is designed to provide drug-free pain relief post-surgery and offers 720 hours of therapy. The partnership aims to strengthen BioElectronics' market presence in Spain, with PRIM handling sales, marketing, and distribution. RecoveryRx is both FDA cleared and CE marked, affirming its compliance with regulatory standards. This move aligns with the company's strategy to expand its distribution network across Europe.

BioElectronics Corporation (OTC: BIEL) announced that its distribution partner in Mexico, Novro Med S.A. de C.V., has obtained authorization from the Mexican FDA (Cofepris) to import the RecoveryRx® device. This marks a significant step for the company as it expands its reach in the Mexican market. The exclusive distribution rights acquired by Novro Med are expected to lead to an initial stocking order in the second quarter of 2022. Marcela Flores, General Manager of Novro Med, expressed enthusiasm for introducing this drug-free pain therapy solution to patients in Mexico.

BioElectronics Corporation has announced significant updates in their recent press release dated February 28, 2022. The company secured contracts with two new international distribution partners, generating over $200,000 in new orders. Key personnel changes include the promotion of Iqra Anwar-Dean to Director of Operations and the hiring of Zoya Atiq as Medical Device Compliance Engineer. Additionally, BioElectronics initiated three clinical studies focusing on pain management and regulatory compliance, emphasizing their commitment to advancing PWST technology and expanding market applications.

BioElectronics Corporation (OTC PINK:BIEL) announced that its largest lenders, Ibex LLC and St. John’s LLC, have agreed to forgo interest on convertible debt notes for the third consecutive year, saving over $1.5 million. The company is engaged in several research projects, including the use of pulsed short-wave therapy (PSWT) to treat psychological disorders, a study on arthritis in dogs, and exploring pain relief for chronic wounds. BioElectronics aims to expand its technology's use for various chronic pain disorders, signaling ongoing commitment to research and development.